Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice.
Miralles López JC, Andújar-Espinosa R, Bravo-Gutiérrez FJ, Castilla-Martínez M, Flores-Martín I, Alemany-Francés ML, Pajarón-Fernández MJ, Mora González A, Valverde-Molina J, Pérez-Fernández V; RE-ASGRAMUR GROUP. Miralles López JC, et al. Among authors: mora gonzalez a. J Investig Allergol Clin Immunol. 2022 Jun 20;32(3):220-223. doi: 10.18176/jiaci.0793. Epub 2022 Feb 15. J Investig Allergol Clin Immunol. 2022. PMID: 35166673 Free article. No abstract available.
Analysis of response of severe eosinophilic asthmatic patients to benralizumab.
Miralles-López JC, Andújar-Espinosa R, Bravo-Gutiérrez FJ, Castilla-Martínez M, Flores-Martín I, Alemany-Francés ML, Pajarón-Fernández MJ, Mora-González A, Cabrejos-Perotti S, El-Molaka Z, Meseguer-Arce J, Avilés-Inglés MJ, Valverde-Molina J, Pérez-Fernández V; RE-ASGRAMUR Group. Miralles-López JC, et al. Among authors: mora gonzalez a. Allergol Immunopathol (Madr). 2022 Nov 1;50(6):163-168. doi: 10.15586/aei.v50i6.704. eCollection 2022. Allergol Immunopathol (Madr). 2022. PMID: 36335460
Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
Bravo-Gutiérrez FJ, Miralles-López JC, Valverde-Molina J, Alemany Francés ML, Andújar-Espinosa R, Castilla-Martínez M, Avilés-Inglés MJ, Mora-González A, Pajarón-Fernández MJ, Cabrejos-Perotti S, Meseguer-Arce J, Flores Martín I, Pérez-Fernández V; RE-ASGRAMUR Group. Bravo-Gutiérrez FJ, et al. Among authors: mora gonzalez a. Int Arch Allergy Immunol. 2024;185(3):253-259. doi: 10.1159/000534902. Epub 2023 Nov 30. Int Arch Allergy Immunol. 2024. PMID: 38035559
Baker's asthma caused by Saccharomyces cerevisiae in dry powder form.
Belchi-Hernandez J, Mora-Gonzalez A, Iniesta-Perez J. Belchi-Hernandez J, et al. Among authors: mora gonzalez a. J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):131-4. doi: 10.1016/s0091-6749(96)70293-2. J Allergy Clin Immunol. 1996. PMID: 8568127 No abstract available.
Determination of eosinophil rate after nasal provocation test in allergic rhinitis diagnosis.
Escudero Pastor A, Negro Alvarez JM, Sola Pérez J, Soriano Gomis V, Mora González A, Sánchez-Guerrero Villajos I, García Sellés FJ, López Sánchez JD, Pagán Alemán JA, Campos Aranda M, et al. Escudero Pastor A, et al. Among authors: mora gonzalez a. Allergol Immunopathol (Madr). 1992 Sep-Oct;20(5):201-5. Allergol Immunopathol (Madr). 1992. PMID: 1292329
Assembling the Dead, Gathering the Living: Radiocarbon Dating and Bayesian Modelling for Copper Age Valencina de la Concepción (Seville, Spain).
García Sanjuán L, Vargas Jiménez JM, Cáceres Puro LM, Costa Caramé ME, Díaz-Guardamino Uribe M, Díaz-Zorita Bonilla M, Fernández Flores Á, Hurtado Pérez V, López Aldana PM, Méndez Izquierdo E, Pajuelo Pando A, Rodríguez Vidal J, Wheatley D, Bronk Ramsey C, Delgado-Huertas A, Dunbar E, Mora González A, Bayliss A, Beavan N, Hamilton D, Whittle A. García Sanjuán L, et al. Among authors: mora gonzalez a. J World Prehist. 2018;31(2):179-313. doi: 10.1007/s10963-018-9114-2. Epub 2018 May 19. J World Prehist. 2018. PMID: 29962659 Free PMC article.
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L, Olvera-Montaño O, Mercado-Sesma AR, Oregon-Miranda AA, Lizárraga-Corona A, Ochoa-Tabares JC, Pérez-Balbuena AL, Montoya-Sánchez IM, Saucedo-Rodríguez LR, Mora-González A, Gómez-Bastar PA, Villanueva-Najera MA, Sandoval-Delgadillo LI, González-Lomelí M, Páez-Garza JH, Orozco-Carroll M, Casillas-Magallanes M. Baiza-Durán L, et al. Among authors: mora gonzalez a. J Ocul Pharmacol Ther. 2018 Apr;34(3):250-255. doi: 10.1089/jop.2017.0056. Epub 2018 Jan 11. J Ocul Pharmacol Ther. 2018. PMID: 29624493 Clinical Trial.